Cargando…

A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry

This study aimed to develop a nomogram to predict fluorescence in situ hybridization (FISH) assay results for HER2-borderline breast cancer as determined via immunohistochemistry (IHC) among patients in China. We reviewed a database of breast cancer patients diagnosed between January 2007 and April...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Qianqian, Chen, Kai, Lin, Xiaojie, Su, Yi, Xu, Rui, Dai, Yan, Qiu, Chang, Song, Xue, Mao, Siying, Chen, Qianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706813/ https://www.ncbi.nlm.nih.gov/pubmed/29212167 http://dx.doi.org/10.18632/oncotarget.19313

Ejemplares similares

Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer
por: Chen, Ming, et al.
Publicado: (2014)

Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
por: Nistor, Andreea, et al.
Publicado: (2006)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
por: Ardor, Gokce Deniz, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
por: Rakha, Emad A., et al.
Publicado: (2021)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer
por: Bae, Young Kyung, et al.
Publicado: (2012)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer
por: Liu, Xuechao, et al.
Publicado: (2016)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
por: Fornaro, Lorenzo, et al.
Publicado: (2019)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
por: Palm, Christiane, et al.
Publicado: (2023)

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
por: Halon, Agnieszka, et al.
Publicado: (2012)

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus
por: Rygiel, Agnieszka M., et al.
Publicado: (2010)

Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases
por: Carretero-Barrio, Irene, et al.
Publicado: (2023)

HER2 Status Determination: Analyzing the Problems to Find the Solutions
por: Terrenato, Irene, et al.
Publicado: (2015)

Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma
por: Dai, Shu-Qin, et al.
Publicado: (2013)

Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China
por: Xu, Chen, et al.
Publicado: (2022)

Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry
por: ZHU, GUANG-JUN, et al.
Publicado: (2014)

FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics
por: Petroni, Stella, et al.
Publicado: (2016)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+ breast cancers: a 2538-case multicenter study on consecutive surgical specimens
por: Yang, Libo, et al.
Publicado: (2018)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma
por: Xu, Aqiao, et al.
Publicado: (2022)

Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: A multicenter study
por: Fang, Caiyun, et al.
Publicado: (2022)

Development and Validation of an Ultrasound-Based Radiomics Nomogram for Identifying HER2 Status in Patients with Breast Carcinoma
por: Guo, Yinghong, et al.
Publicado: (2022)

Determination of HER2 Amplification Status on Tumour DNA by Digital PCR
por: Garcia-Murillas, Isaac, et al.
Publicado: (2013)

Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
por: Cardillo, Anthony B., et al.
Publicado: (2023)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

Immunohistochemistry of mammary Paget’s disease: Cytokeratin 7, GATA3, and HER2 are sensitive markers
por: Arain, Shoukat A., et al.
Publicado: (2020)

Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
por: Shi, Hong-Zhi, et al.
Publicado: (2017)

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing
por: Werner, Dominique, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m3bhpob2g329ur6r1bfum1u1u0